The Technical Analyst
Nuwellis, Inc. [NUWE]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Nuwellis, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
14.64% US12542Q700.289
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.966 mill |
| EPS: | -11.52 |
| P/E: | -0.0300 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 6.80 mill |
| Avg Daily Volume: | 0.839 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0300 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0300 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
US12542Q70 0.248 - 0.336 ( +/- 15.05%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-02 | Mccormick Michael Kendrick | Buy | 20 836 | Nonstatutory Stock Option (right to buy) |
| 2024-01-02 | Mcdonald David | Buy | 11 365 | Nonstatutory Stock Option (right to buy) |
| 2024-01-02 | Feldshon Archelle Georgiou | Buy | 11 365 | Nonstatutory Stock Option (right to buy) |
| 2023-11-01 | Mcdonald David | Buy | 0 | |
| 2023-11-01 | Feldshon Archelle Georgiou | Buy | 0 |
| INSIDER POWER |
|---|
| 97.92 |
| Last 90 transactions |
| Buy: 3 285 386 | Sell: 12 287 |
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - US12542Q700.294
Forecast 2: 16:00 - US12542Q700.294
Forecast 3: 16:00 - US12542Q700.294
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | US12542Q700.289 (14.64% ) |
| Volume | 9.82 mill |
| Avg. Vol. | 0.839 mill |
| % of Avg. Vol | 1 170.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NUWE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NUWE
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Latest Press Releases
2024-03-07 09:08:00 - Press Release
Late-breaking Data Highlighting Benefits Of Ultrafiltration Therapy Using The Aquadex System For Heart Failure Patients Was Presented At The Technology And Heart Failure Therapeutics Conference
- analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failure hospitalizations compared to intravenous loop diuretics- artificial intelligence and machine learning-based model show that lifestyle and clinical factors can be strong predictors of heart failure events
2024-03-05 08:00:00 - Press Release
Nuwellis, Inc. Announces Fourth Quarter And Full Year 2023 Financial Results
Strengthens its foundation for growth, strong pediatric sales, expanding margins and increases number of new hospital accounts strengthens its foundation for growth, strong pediatric sales, expanding margins and increases number of new hospital accounts
2024-02-27 09:00:00 - Press Release
Nuwellis, Inc. To Report Fourth Quarter And Full Year 2023 Financial Results on March 5, 2024
Minneapolis, feb. 27, 2024 (globe newswire) -- nuwellis, inc. (nasdaq: nuwe), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year of 2023 on tuesday, march 5, 2024. nuwellis will host a conference call and webcast at 9:00 am et to discuss its financial results and provide a general business update.
2024-02-22 07:58:00 - Press Release
Nuwellis' Distribution Partner, Seastar Medical, Receives Fda Humanitarian Device Exemption For Pediatric Selective Cytopheretic Device Quelimmune™
Minneapolis, feb. 22, 2024 (globe newswire) -- nuwellis, inc. (nasdaq: nuwe), a medical technology company focused on transforming the lives of people with fluid overload, today announced its distribution partner, seastar medical holding corporation (nasdaq: icu) (seastar medical), has received humanitarian device exemption (hde) from the u.s. food and drug administration (fda) for quelimmune™, its pediatric selective cytopheretic device. quelimmune provides a new therapy option for children weighing 10 kg or more who have acute kidney injury (aki) and sepsis or a septic condition requiring continuous kidney replacement therapy (ckrt) in a hospital intensive care unit.
2024-02-20 17:06:00 - Press Release
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Minneapolis, feb. 20, 2024 (globe newswire) -- nuwellis, inc. (nasdaq: nuwe) today announced that, effective february 20, 2024, the company's independent directors approved equity awards under nuwellis' 2021 inducement plan, as material inducements to two individuals entering into employment with the company. the equity awards were approved in accordance with nasdaq listing rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder-approved equity plan.
Latest News
2024-02-27 09:00:00 - GlobeNewsWire
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year of 2023 on Tuesday, March 5, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.
2024-02-20 08:42:00 - GlobeNewsWire
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system
2023-11-13 11:18:13 - Zacks Investment Research
Here's Why Nuwellis, Inc. (NUWE) Is a Great 'Buy the Bottom' Stock Now
Nuwellis, Inc. (NUWE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2023-11-07 14:06:03 - Seeking Alpha
Nuwellis, Inc. (NUWE) Q3 2023 Earnings Call Transcript
Nuwellis, Inc. (NASDAQ:NUWE ) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President and CEO John Jefferies - Chief Medical Officer Rob Scott - CFO Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Anthony Vendetti - Maxim Group Operator Good day, and welcome to the Nuwellis third-quarter 2023 earnings conference call. [Operator Instructions].
2023-10-18 16:15:00 - GlobeNewsWire
Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023
MINNEAPOLIS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its third quarter 2023 financial results will be released on Tuesday, November 7, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.
2023-09-11 16:15:00 - GlobeNewsWire
Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase
MINNEAPOLIS, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that President and Chief Executive Officer Nestor Jaramillo, Chief Financial Officer Rob Scott, and Chief Medical Officer Dr. John Jefferies, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 12:00 pm ET.
2023-09-11 09:19:57 - InvestorPlace
Why Is Nuwellis (NUWE) Stock Down Today?
Nuwellis (NASDAQ: NUWE ) stock is taking a beating on Monday despite a lack of news concerning the medical device company. In fact, there's really not much in the way of anything to report about Nuwellis stock today.
2023-07-18 16:15:00 - GlobeNewsWire
Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023
MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its second quarter 2023 financial results will be released on Tuesday, August 8, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.
2023-02-23 16:15:00 - GlobeNewsWire
Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference
MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor Jaramillo, President and Chief Executive Officer, and Lynn Blake, Chief Financial Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023.
2023-02-07 08:00:00 - GlobeNewsWire
Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
MINNEAPOLIS, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023. The company will host a conference call and webcast at 8:30 AM ET, during which management will discuss the company's financial results and provide a general business overview.